Insider Transactions in Q1 2023 at Lexicon Pharmaceuticals, Inc. (LXRX)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 28
2023
|
Wendy Mc Dermott VP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
6,465
-34.13%
|
$12,930
$2.17 P/Share
|
|
Feb 28
2023
|
Wendy Mc Dermott VP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
18,943
+50.0%
|
-
|
|
Feb 28
2023
|
Kiernan Seth VP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,813
-18.19%
|
$23,626
$2.17 P/Share
|
|
Feb 28
2023
|
Kiernan Seth VP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
43,082
+22.03%
|
-
|
|
Feb 28
2023
|
Kristen Alexander VP, Finance and Accounting |
SELL
Payment of exercise price or tax liability
|
Direct |
5,330
-14.94%
|
$10,660
$2.17 P/Share
|
|
Feb 28
2023
|
Kristen Alexander VP, Finance and Accounting |
BUY
Exercise of conversion of derivative security
|
Direct |
18,717
+17.37%
|
-
|
|
Feb 28
2023
|
Jeffrey L Wade President and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
30,255
-11.1%
|
$60,510
$2.17 P/Share
|
|
Feb 28
2023
|
Jeffrey L Wade President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
78,916
+9.51%
|
-
|
|
Feb 28
2023
|
Brian T Crum SVP, General Counsel & Secr. |
SELL
Payment of exercise price or tax liability
|
Direct |
20,537
-13.22%
|
$41,074
$2.17 P/Share
|
|
Feb 28
2023
|
Brian T Crum SVP, General Counsel & Secr. |
BUY
Exercise of conversion of derivative security
|
Direct |
55,877
+11.86%
|
-
|
|
Feb 28
2023
|
Craig B Granowitz SVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,732
-45.61%
|
$25,464
$2.17 P/Share
|
|
Feb 28
2023
|
Craig B Granowitz SVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
27,917
+50.0%
|
-
|
|
Feb 28
2023
|
Kenneth B. Kassler Taub SVP, Regulatory & QA |
SELL
Payment of exercise price or tax liability
|
Direct |
19,118
-13.78%
|
$38,236
$2.17 P/Share
|
|
Feb 28
2023
|
Kenneth B. Kassler Taub SVP, Regulatory & QA |
BUY
Exercise of conversion of derivative security
|
Direct |
52,886
+12.49%
|
-
|
|
Feb 28
2023
|
Alan J Main EVP, Innov & Chem Sciences |
SELL
Payment of exercise price or tax liability
|
Direct |
20,946
-8.97%
|
$41,892
$2.17 P/Share
|
|
Feb 28
2023
|
Alan J Main EVP, Innov & Chem Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
57,943
+8.18%
|
-
|
|
Feb 28
2023
|
Lonnel Coats Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
50,971
-6.41%
|
$101,942
$2.17 P/Share
|
|
Feb 28
2023
|
Lonnel Coats Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
209,327
+8.68%
|
-
|